We observed mutant KRAS fragments in 9 of 17 (52.9%) late-stage pancreatic cancer samples vs. 7 of 20 (35%) control samples after collectively targeting 7 different KRAS alterations in the cfDNA (Fig. 6; Supplementary Table S2). The gene discussed is KRAS; the disease is familial pancreatic carcinoma.